13
Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona ASSESSMENT OF CAROTID ATHEROSCLEROSIS IN MY CLINICAL PRACTICE

Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Embed Size (px)

DESCRIPTION

Subclinical Atherosclerosis Adapated from Naqvi TZ, Lee MS. JACC Cardiovasc Imaging.Adapated from Naqvi TZ, Lee MS. JACC Cardiovasc Imaging Oct;7(10):

Citation preview

Page 1: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE

Director EchocardiographyProfessor of Medicine, College of Medicine

Mayo Clinic, Scottsdale, Arizona

ASSESSMENT OF CAROTID ATHEROSCLEROSIS IN MY CLINICAL PRACTICE

Page 2: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Carotid Bifurcation US Femoral Bifurcation US

Arterial Segments Commonly Involved in Atherosclerosis

Page 3: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Subclinical Atherosclerosis

Adapated from Naqvi TZ, Lee MS. JACC Cardiovasc Imaging. 2014 Oct;7(10):1025-38

Page 4: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Value in Clinical Practice

Page 5: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

53 yr old male T chol: 251HDL 53LDL 167TG 70Framingham risk:11%

Case

Page 6: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

61 yr old female Total cholesterol 216HDL 50LDL 143Triglycerides 239 mg/dlFRS 6%

Case

Page 7: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Case: My patient is not compliant..

50 yr old Caucasian female, history of DM, non compliant with diet or lipid lowering agents

Page 8: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona
Page 9: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Case: 45 year old maleHTN,h/o of RCA stent 3 yrs ago,

-ve stress echoWould not take statins

Page 10: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Case: 45 year old male

HTN,h/o of RCA stent 3 yrs ago, -ve stress

echoWould not take statins

Page 11: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Case: I am Intolerant to Statins and Would not

take’m67 MCABGInf MI, EF 40%Recent LCX Stent

Naqvi TZ. J Am Soc Echocardiogr. 2015 May; 28(5):A16-7

Page 12: Tasneem Z Naqvi, MD, FRCP (UK), MMM, FACC, FASE Director Echocardiography Professor of Medicine, College of Medicine Mayo Clinic, Scottsdale, Arizona

Summary

CIMT and plaque imaging is feasible in clinical practice in primary prevention setting and can improve CVD risk prediction over conventional methods

CIMT and plaque imaging can detect atherosclerosis burden in secondary prevention setting and improve patient compliance

Common Carotid